Dual targeted therapy with pyrotinib and trastuzumab for<scp>HER2</scp>‐positive advanced colorectal cancer: A phase 2 trialXianhua Fu, Ying Yuan, Jieer Ying et al.|Cancer Science|2022Cited by 29
Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of responseJingjing Li, Jieer Ying, Xiaoying Wu et al.|Clinical and Translational Medicine|2020Cited by 24
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)Jianming Xu, Weiguo Su, Lin Shen et al.|European Journal of Cancer|2025Cited by 4
1057P Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumorsJ. Li, Lin Shen, Ye Xu et al.|Annals of Oncology|2023Cited by 0